AstraZeneca, the Cambridge-based pharmaceutical giant, is in talks with U.S. rival Bristol Myers Squibb over a potential merger that would create a combined group worth close to $400 billion, according to a report by the Financial Times confirmed by multiple outlets including Reuters and CNBC.
The talks, which people familiar with the matter say have been ongoing for several months, remain fluid: a deal could be finalized in the coming weeks, but could equally stall or collapse altogether, as is often the case with megadeals of this size. Neither company has publicly commented on the discussions.
AstraZeneca currently carries a market capitalization of roughly $263 billion, while Bristol Myers Squibb is valued at around $133 billion. Should the merger go through on the terms reportedly under discussion, likely a mix of cash and stock, the enlarged company would become the world’s fourth-largest drugmaker by market value, and would represent by far the biggest acquisition in AstraZeneca’s history, eclipsing its $39 billion purchase of Alexion Pharmaceuticals in 2021.
The strategic logic is clear on both sides. AstraZeneca, led for the past fourteen years by chief executive Pascal Soriot, under whom the company’s share price has roughly quadrupled, has built its growth around oncology and rare-disease treatments, which generated close to $25 billion in sales in 2025, nearly half of total group revenue. A tie-up with Bristol Myers Squibb, whose own oncology drugs, including the immunotherapy Opdivo and the blood thinner Eliquis, account for more than 40 percent of first-half 2026 sales, would significantly deepen AstraZeneca’s foothold in the lucrative U.S. cancer-drug market.
For Bristol Myers Squibb, whose shares have risen 44 percent over the past year on the back of stronger-than-expected results, the deal would offer a hedge against a looming patent cliff, with several of its best-selling drugs due to lose exclusivity by 2028. The company’s pipeline, including the experimental blood thinner milvexian, anemia treatment Reblozyl and heart drug Camzyos, would gain the backing of AstraZeneca’s larger global commercial infrastructure.
Any deal would nonetheless face serious regulatory hurdles. Both companies hold substantial, overlapping oncology and immunotherapy portfolios, a combination that antitrust regulators in the United States, the European Union and the United Kingdom are likely to scrutinize closely. British officials, wary of a UK-headquartered company shifting its center of gravity toward the U.S. market, are also expected to watch the negotiations with interest.
The reported approach comes twelve years after AstraZeneca famously rebuffed a $118 billion takeover bid from Pfizer in 2014, a defense widely credited with cementing Soriot’s reputation as one of the pharmaceutical industry’s most combative dealmakers. Should this new combination materialize, it would mark one of the largest corporate mergers of the decade and reshape the competitive landscape of global oncology drug development for years to come.
Shares of both companies were closely watched by investors following the report, with pharmaceutical sector analysts noting that a successful merger would intensify consolidation pressure across an industry already grappling with looming patent expirations and pricing reforms in major markets. A formal announcement, if the talks progress, is not expected before both companies’ boards conclude their respective reviews.
